CCCC — C4 Therapeutics Balance Sheet
0.000.00%
- $123.55m
- -$121.35m
- $35.58m
Annual balance sheet for C4 Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 372 | 309 | 276 | 254 | 245 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4.48 | 5.72 | 1.47 | 11.8 | 3.1 |
Prepaid Expenses | |||||
Total Current Assets | 381 | 326 | 288 | 271 | 258 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 16.6 | 35.1 | 77.5 | 71.1 | 63.4 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 400 | 507 | 431 | 376 | 350 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 43.9 | 51.2 | 44.5 | 42.8 | 45.2 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 119 | 117 | 142 | 130 | 134 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 281 | 390 | 289 | 246 | 216 |
Total Liabilities & Shareholders' Equity | 400 | 507 | 431 | 376 | 350 |
Total Common Shares Outstanding |